Introduction y-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system. The predominant effect of GABA is the interaction with a specific receptor protein which results in an increase of the chloride ion conductance of the post-synaptic membrane to produce an inhibition of neuronal firing. In recent years, much attention has been focused on this specific receptor, the GABAA receptor, and the reasons for this are two-fold. Firstly, the pharmacology of the receptor is extremely rich and a minimum of three interacting allosteric drug binding sites are known to occur within the same receptor oligomer. These include those for the site of action of the tranquillizer drugs, the benzodiazepines, and the central nervous system depressant barbiturates. Secondly, and uniquely, opposing pharmacological actions appear to be mediated through this one receptor protein. Thus compounds which interact at the benzodiazepine site can be anxiolytic, as exemplified by the often-prescribed valium, or conversely they can have anxiogenic and convulsant properties; this phenomenon has led to the unorthodox concept of the 'inverse agonist' (Haefely & Polc, 1986) .
The purpose of this review is to present current views on the molecular structure of the GABAA receptor, as derived from biochemical investigations. Included also will be an exciting new development in this field, the indication that the neurotransmitter receptor proteins that are ligand-gated ion channels, that is the nicotinic acetylcholine receptor, the GABAA receptor, the glycine receptor and possibly the receptors for the excitatory amino acids, belong to a superfamily of chemically gated ion channels.
GABA receptor classification
While this review will consider in detail the structure of the GABAA receptor, it is important to note that there does exist a multiplicity of GABA receptors that were defined originally on a pharmacological basis. The most studied of the GABA receptors is the GABAA receptor of the vertebrate central nervous system (Olsen & Venter, 1986) . GABAA receptors have a wide distribution in the brain, with the highest density being found in the frontal cerebral cortex and the granule cell layer ofthe cerebellum (Bowery et al., 1987) . Early studies showed that the action of GABA was to cause a rapid increase in the neuronal membrane permeability to chloride ions and that this response could be antagonized in a competitive manner by the compound bicuculline (for review, see Turner & Whittle, 1983) . Thus it was hypothesized that the GABAA receptor is analogous to the well-characterized nicotinic acetylcholine receptor in that it is a ligand-gated ion channel with a binding site for the natural activator, GABA, and intrinsic to the receptor is the functional response, the chloride ion channel (McCarthy et al., 1986 ). An important advance in the biochemical investigations of the GABAA receptor was the realization that the anxiolytic benzodiazepine drugs act by a facilitation of GABAergic neurotransmission (for review see Olsen & Venter, 1986) . This potentiation has been extensively characterized at the functional level, where electrophysiological studies have shown that in the presence of GABA the benzodiazepines cause an increase in the frequency of chloride channel opening, thus facilitating and increasing the efficiency of the GABA transmission (Study & Barker, 1981) . Moreover, studies at the biochemical level by ligand-binding methods have demonstrated the presence of benzodiazepine binding sites in the brain (Squires & Braestrup, 1977) and their non-competitive but allosteric interaction and thus association with GABA receptor sites (Olsen & Venter, 1986) . Similarly, it has been shown conclusively by both electrophysiological and biochemical means that the barbiturate drugs facilitate GABA neurotransmission, akhough their mechanism of action is distinct from that of the benzodiazepines: in the presence of GABA, they cause an increase in the mean open time of the chloride ion channel (Study & Barker, 1981) . Interestingly, two other classes of compounds have recently been shown to interact specifically and with high affinity with GABAA receptors. These are the anthelminthic avermectins (Pong & Wang, 1982) and some steroids which include the steroidal anaesthetic alfaxalone (Harrison & Simmonds, 1984) and derivatives of progesterone (Lambert et al., 1987) .
GABAA-mediated responses are not found exclusively in the central nervous system, and recently they have been described in the peripheral nervous system e.g. in rabbit uterus (Erdo, 1985) , in guinea pig ileum (Ong & Kerr, 1983) and in the adrenal chromaffin cell (Bormann & Clapham, 1985) . The peripheral GABAA receptors have the same drug regulatory properties as those that are found in the central nervous system, i.e. benzodiazepine, barbiturate and steroid potentiation (Ong & Kerr, 1984; Lambert et al., 1987) .
GABA receptors are found also in invertebrate nervous systems. The GABA-mediated responses are similar to those of the vertebrate A-type, in that they are fastacting chloride channel conductance changes that are potentiated by both the benzodiazepines and the barbiturates (Beadle et al., 1986) . The antagonism (Lummis & Sattelle, 1986) and binding studies in housefly (Musca domestica) heads and locust (Schistocerca gregaria) supraoesophageal ganglia have shown that the benzodiazepine potentiation is dependent upon divalent cations and has a pharmacology distinct from that of the vertebrates (Robinson et al., 1986) .
GABAB receptors have so far been described only in the mammalian central and peripheral nervous systems. GABAB receptors differ from the A-type in both pharmacology and effector mechanisms. They are characterized by the binding of the GABAB-receptor-specific ligand (-)-baclofen; additionally, they are bicucullineinsensitive and the measurement of GABAB receptor binding is dependent on divalent cations Bowery et al., 1983) . The benzodiazepines and the barbiturates do not interact with the GABAB receptor.
GABAB receptors appear to regulate Ca2" (Holz et al., 1986) and/or K+ channel activity (Inoue et al., 1985) , and they have been shown to modulate adenylate cyclase activity via an interaction with a GTP binding protein (Wojcik & Neff, 1984; Karbon & Enna, 1985; Hill, 1985) . Thereby they belong to the second-messengermediated receptor class (Strange, 1988) . Whereas GABAA receptors are thought to be predominantly postsynaptic, GABAB receptors are found both pre-and post-synaptically. They are less abundant than GABAA receptors in the central nervous system; nevertheless, their occurrence is widespread and their pattern of distribution is distinct from that of the GABAA receptor (Wilkin et al., 1981; Bowery et al., 1987) .
There is a third class of GABA receptor sites inferred from binding studies, which is both bicuculline-and (-)-baclofen-insensitive (Drew et al., 1984) . Ault & Nadler (1983) provided electrophysiological evidence that such responses could be found in rat hippocampal slices, and these have been tentatively denoted GABAC responses (Drew et al., 1984) . The reinainder of this review will consider exclusively the structural investigations of the GABAA receptor from mammalian brain.
GABAA receptor isolation
Solubilization studies. The GABAA receptor is an integral membrane protein and a prerequisite for the purification of the receptor is the solubilization of the protein in a functional state. The functional state is defined for this purpose as the preservation in detergent solution of the ligand-binding properties and the corresponding allosteric interactions between these sites. Specifically these sites for direct binding are: (i) the GABA binding site, which is usually measured with the high-affinity GABA agonist [3H] Tallman & Gallager, 1985) . The structures of some of these ligands are shown in Fig. 1 .
In the earlier studies of receptor solubilization it was found that most common non-denaturing detergents, both ionic and non-ionic, readily solubilized the mammalian GABAA receptor from brain membrane preparations (reviewed in . In the presence of these detergents, however, the binding sites for the chloride channel gating ligands were not detectable when assayed either by direct binding or by the allosteric effects on GABA and benzodiazepine binding . The detergent CHAPS, which is a zwitterionic derivative of cholic acid, has been shown to solubilize (although in lower yield), active GABA, benzodiazepine and TBPS binding sites in parallel Trifiletti et al., 1984; Stephenson et al., 1984) . Furthermore, the barbiturate regulation of benzodiazepine and GABA (Stephenson & Olsen, 1983) binding is preserved in the corresponding CHAPS extracts. GABA and benzodiazepine binding sites are stable in the presence of CHAPS detergent and protease inhibitors, but the other effects associated with the channel gating readily inactivate with storage . Bristow & Martin (1987) The purification of the GABAA receptor has been achieved so far, therefore, only by benzodiazepine affinity chromatography. This exploits the coexistence of the GABAA and benzodiazepine binding sites within the same receptor oligomer. The isolation of the receptor from various vertebrate species has now been reported by several groups (Martini et al., 1982 (Martini et al., , 1983 Sigel et al., 1982 Sigel et al., , 1983 Olsen et al., 1984; Schoch et al., 1984; Taguchi & Kuriyama, 1984; Kirkness & Turner, 1986a) . The structures of the benzodiazepine affinity columns that have been used all have the same design, in that the benzodiazepine is covalently bound to a solid support via a spacer arm. Minor differences in the affinity column structures are reflective of the benzodiazepine chosen for immobilization . The benzodiazepines that have been used for the affinity chromatography have affinities in the KD approx 20-100 nm range for the central benzodiazepine receptor sites. Essentially, the isolation is a one-step purification procedure, in which the soluble brain extract in the presence of protease inhibitors is applied to the benzodiazepine affinity column; the column is extensively washed to remove the protein that is bound nonspecifically by both hydrophobic and electrostatic interactions; the purified receptor is recovered by the biospecific elution with a water-soluble benzodiazepine agonist, both chlorazepate (Sigel et al., 1983; Kirkness & Turner, 1986a) and flurazepam Tallman, 1984) having been employed. The benzodiazepine is then removed by either ion-exchange chromatography (Sigel et al., 1983) , gel filtration Schoch et al., 1984) or diafiltration (Tallman, 1984) .
The purification is an inefficient process with respect to the yield as determined by activity measurements. A range of 2-5 % of the original benzodiazepine binding starting activity has been reported (Sigel et al., 1983; Kirness & Turner, 1986a) . The major loss of activity was found to occur at the benzodiazepine affinity column chromatography elution step, where generally 14-20% of the bound sites are recovered in an active state (Sigel et al., 1983; Kirkness & Turner, 1986a) . It has been demonstrated that despite the low recovery always considered a problem in membrane protein isolation, the pharmacological and physiological properties of the purified protein are representative of the population of receptors found in the membrane-bound state.
The binding properties and pharmacological specificity of the purified GABAJ/benzodiazepine receptor First, the purified material was shown to contain a single high-affinity binding site for benzodiazepine Vol. 249 agonists (Martini et al., 1982; Sigel et al., 1983; Olsen et al., 1984; Schoch et al., 1984; Taguchi & Kuriyama, 1984; Kirkness & Turner, 1986a) , antagonists and the anxiogenic ligands, the inverse agonists, e.g. methyl ,3-carboline-3-carboxylate (Schoch & Mohler, 1983) . The number of benzodiazepine agonist binding sites equals the number of benzodiazepine antagonist binding sites . This binding site has 'central' benzodiazepine receptor specificity; for a series of centrally acting benzodiazepines the rank order of potency at the purified benzodiazepine binding site correlates well with the potency at the membrane-bound receptor site (Squires & Braestrup, 1977; Mohler & Richards, 1981) , and with evaluations in vivo of both the anxiolytic and anticonvulsant potencies of benzodiazepines (Tallman et al., 1980) . Second, by direct binding studies the purified receptor was shown to possess also a single high-affinity binding site for the GABA agonist, [3H]muscimol (Sigel et al., 1982 (Sigel et al., , 1983 Olsen et al., 1984; Schoch et al., 1984; Taguchi & Kuriyama, 1984; Kirkness & Turner, 1986a) . This binding site has GABAA receptor specificity, i.e. in the binding assays the activity is sensitive to the GABA antagonist bicuculline but not to ligands which are specific for the GABAB binding site or for the Na+-dependent GABA uptake system (Sigel et al., 1983) . Again for a series of GABA agonists, the rank order of potency at the purified GABA binding site correlates with the potency at the membrane-bound GABA binding site (Greenlee et al., 1978; Olsen et al., 1981 ) (i.e. high-and low-affinity sites) and with the neurophysiological activity on the vertebrate nervous system (Krogsgaard-Larsen et al., 1975; Krogsgaard-Larsen & Johnston, 1978) . The concentrations that are required for receptor binding are up to three orders of magnitude lower than the micromolar concentrations of GABA that are needed to evoke GABA-induced conductance changes in neurons (e.g. Barker & Owen, 1986) . However, the same discrepancies exist for the binding of GABA to the membrane-bound receptor (Olsen, 1982) and the correlation that is found for the series of GABA agonists in both systems is very good.
Third, the positively co-operative effect of GABA on benzodiazepine binding affinity is found in the purified protein. In a sodium deoxycholate/Triton-purified bovine receptor, the maximum stimulation of benzodiazepine binding activity was 20 % in the presence of GABA with respect to control samples . The concentrations of GABA that are seen to stimulate benzodiazepine binding activity to the purified protein are at least an order of magnitude higher than those required for receptor binding. Thus, this has been called the 'low affinity' GABA site and reported EC50 values are 1 UM or 0.1 m (Schoch et al., 1984) .
The binding properties ofthe purified GABAA receptor reflect the binding properties that are retained following membrane-protein solubilization. Accordingly, it has been shown that when brain membranes are extracted with CHAPS and exogenous phospholipid in the form of asolectin ; CHAPS and L-aphosphatidylcholine (Kirkness & Turner, 1986a) or with CHAPS alone (Stephenson et al., 1986a ) and subsequently purified in the same media, specific TBPS binding Stephenson et al., 1986a) and barbiturate and anaesthetic propanidid (Kirkness & Turner, 1986a,b) facilitation of both benzodiazepine and GABA binding were retained in the purified GABAA receptor. It was shown, however, that all of the above-mentioned properties that are associated with the direct gating of the chloride ion channel, although present in the purified protein, are both readily inactivated and decreased in magnitude when compared with the properties that are found for the membrane-bound or crude soluble receptor. Interestingly, it has been found that the presence of phospholipid throughout the isolation scheme is requisite for the stabilization of the TBPS binding site. Stephenson et al. (1986a) showed that for the bovine receptor extracted with CHAPS alone and purified in the presence of CHAPS with no added phospholipid, the TBPS specific binding activity was not detectable in the purified receptor, although it was present in the correct stoichiometric concentration in the CHAPS crude brain extract. Havoundjian et al. (1986) observed that phospholipase A2 treatment of rat brain membranes decreased both TBPS binding and barbiturate-enhanced benzodiazepine binding activity. Furthermore, as described earlier, Bristow & Martin (1987) found that in CHAPS crude extracts the replacement of asolectin with a natural brain lipid extract supplemented with cholesterol hemisuccinate stabilized both the barbiturate-and cartazolateenhanced benzodiazepine binding activity. All these observations suggest that the presence of phospholipid and the nature of the protein-lipid interactions, as yet unspecified, are critical for the integrity of the channel gating site. In contrast with the results of Stephenson et al. (1986a) , King et al. (1987) found that the convulsant TBPS binding activity is reversibly inactivated in the presence of sodium deoxycholate or Triton. Following extraction with sodium deoxycholate or Triton, exchange by CHAPS was found to restore TBPS binding to both impure and purified preparations. These observations have been interpreted as a reflection of the different conformational states of the receptor protein which can be induced by the detergent used for extraction (King et al., 1987) .
Binding site stoichiometry of the isolated GABAA receptor While there is a consensus concerning the binding sites that coexist in the isolated GABAA receptor oligomer, the binding site stoichiometry is still uncertain. The binding site ratios that have been determined for the pure protein are given in Table 1 . Considering firstly the ratio of benzodiazepine to TBPS sites, it can be seen from Table 1 that this value approaches unity . This agrees well with the values that have been determined for both the membrane-bound and crude soluble receptor preparations where the number of benzodiazepine and TBPS sites are equal. Indeed, these respective binding sites have been shown to copurify exactly in the benzodiazepine affinity chromatography purification procedure (Stephenson, 1987) Stephenson, 1987) . With regard to the ratio of GABA to benzodiazepine binding sites in the isolated receptor, values from 1 to 4 have been reported (Table 1 ). It is difficult to rationalize all these observations. It can be noted that in the majority of the preparations where sodium deoxycholate or Triton are employed for membrane protein extraction, the number of GABA sites is greater than the number of benzodiazepine binding sites (Table 1 ). In the presence of CHAPS, the ratio tends to unity, but firstly it must be stated that CHAPS itself has GABA-mimetic properties (Seifert & Casida, 1985) and can inhibit GABA binding directly. Secondly, it has been suggested that CHAPS solubilization may allow the GABA receptor to exist in solution, as in the membrane, in both a high-and a lowaffinity conformation . Thus the determination of the total number of sites is subject to large errors. Electrophysiological studies have demonstrated that the binding of two molecules of agonist is required to open the chloride ion channel (Sakmann et al., 1983; Bormann & Clapham, 1985; Bormann et al., 1987) . The information available from muscimol-photoaffinity labelling studies suggests two agonist binding polypeptides per receptor (see below and Casalotti et al., 1986; Deng et al., 1986) . Thus the accumulated experimental evidence favours a ratio of 1, and the conflicting data may reflect detergent inactivation of the benzodiazepine binding sites. It is clear that further experimentation is required to answer definitively the question of binding site stoichiometry.
Characterization of the purified GABAA receptor Molecular properties. The GABAA receptor is an acidic glycoprotein and the purified bovine receptor has an isoelectric point (pI) of 5.6 (Stephenson et al., 1986b) . The glycoprotein nature of the receptor was demonstrated by the specific binding of the receptor to both concanavalin A and Lens culinaris lectin affinity columns (Gavish & Snyder, 1981; Stephenson & Olsen, 1983; Sigel et al., 1982) and positive periodic acid/Schiffs-base carbohydrate staining of the purified receptor polypeptides following SDS/PAGE . Furthermore the susceptibility of the receptor protein polypeptides, as demonstrated by SDS/PAGE, to enzymic deglycosylation in both the membrane-bound (Sweetnam & Tallman, 1986) and the purified state (Mamalaki et al., 1987) confirms the presence of glycosyl residues on the purified protein.
The molecular mass of the native GABAA receptor oligomer purified from bovine brain has been determined by H20/2H20 sucrose density gradient centrifugation in combination with gel exclusion chromatography (Meunier et al., 1972) for membrane proteins. After the correction for the bound detergent and under conditions which maintained the pure receptor in a non-aggregated monomeric form the minimum size for the sodium deoxycholate/Triton-purified bovine and rat receptor was 230 kDa (Mamalaki et al., 1988) . Under these same conditions of hydrodynamic separation, a similar value of 240 kDa was determined for impure sodium deoxycholate-solubilized receptor (Mamalaki et al., 1988) .
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Significantly, in both these preparations it was shown that the GABAA and benzodiazepine binding activities comigrated in subsequent separation procedures. In the same report, Mamalaki et al. (1988) showed that the molecular mass of the CHAPS/asolectin crude and purified bovine receptor was 290 kDa. This value was shown to be not significantly different from that for the sodium deoxycholate/Triton-purified bovine receptor and again, it was stressed that following the further chromatographic and sucrose gradient sedimentation separations, GABA, benzodiazepine and TBPS binding activities were all shown to comigrate. The group of Olsen (King et al., 1987) has studied the hydrodynamic behaviour of the rat GABAA receptor. In support of the findings of Mamalaki et al. (1988) , they found that for the GABAA receptor solubilized in CHAPS alone and containing convulsant activity, and the GABAA receptor solubilized in CHAPS but supplemented with Triton, i.e. with no expression of TBPS binding, both these preparations did not differ in their hydrodynamic behaviour as measured by gel filtration (King et al., 1987) . Thus the molecular size of the receptor from bovine and rat sources under all detergent conditions is the same. We can conclude, therefore, that it is the expression of the binding activities which is altered rather than an association of the TBPS binding component with an additional protein component which is cosolubilized only with CHAPS detergent. This is an important point, because the reported molecular mass determinations of the GABAA receptor in situ, i.e. in the functional membrane-bound state, by target size radiation inactivation, differ. Values of 50 kDa (Paul et al., 1981 ; Nielsen et al., 1985) , 90-100 kDa (Doble & Iversen, 1982) and 200-220 kDa (Chang et al., 1981; Chang & Barnard, 1982) have been reported for both the GABA and the benzodiazepine binding sites. Indeed, Nielsen et al. (1985) deduced that the target size for the GABA/ benzodiazepine receptor chloride channel complex was 548 kDa. These values are probably all correct and reflect differences in the experimental conditions employed for both the irradiation studies and the method of calibration; thus the observed value may relate to the size of the ligand binding subunit or to the entire receptor oligomer . There is agreement between the hydrodynamic calculations and the target size determined by Barnard's group, the value being 230 kDa. This correlation was evident also between the molecular size of the protein in the purified and crude soluble state, where these studies have been carried out under identical conditions in parallel: the minimum functional size for the purified receptor is in the range 240-290 kDa (Mamalaki et al., 1988) .
GABAA receptor subunit composition. SDS/PAGE of the GABAA receptor from all species examined to date, with the exception of one report by Martini et al. (1982) , has shown that the receptor protein has a heterologous structure. Table 2 summarizes the published results. It can be seen that in the majority of the reports the GABAA receptor has two polypeptide chains; these have been named the a-subunit, with Mr 53000, and the ,-subunit, with Mr 58000 (see Table 2 for references). The same polypeptide pattern was found for SDS/PAGE under reducing and non-reducing conditions (Stephenson, 1987) and most importantly this same subunit composition for the pure GABAA receptor was found Kirkness & Turner (1986a) under all conditions of purification (Sigel et al., 1983; Kirkness & Turner, 1986a and the change in their mobility also in SDS/PAGE following N-linked carbohydrate removal by endoglycosidase F treatment (Mamalaki et al., 1987) . The core sizes of the deglycosylated polypeptides of the pure bovine receptor are: a, Mr 44000; f, Mr 55000 (Mamalaki et al., 1987) . Quantitative densitometric scans of Coomassie Blue stained SDS/PAGE gels of purified receptor have shown that these subunits are (within the errors of these methods) present in equivalent amounts (Mamalaki et al., 1987) . It has been proposed from these findings, in conjunction with the molecular mass determinations, that the GABAA receptor is a heterologous tetramer with stoichiometry a2f82 (Mamalaki et al., 1987) . There is no evidence to support the existence of an Mr 90000 subunit in the CHAPS/asolectin receptor preparations, which has been inferred from the target size irradiation studies of both Nielsen et al. (1985) and Schwartz et al. (19.85) . From Table 2 it can be noted, however, that additional polypeptides with Mr approx. 50000 are sometimes present in the purified GABAA receptor preparations. These will be referred to later.
Photoaffinity labelling of the purified GABAA receptor. It is remarkable that two of the ligands that are used to study the reversible binding properties of the GABAA receptor, flunitrazepam and muscimol (Fig. 1) , have the property that they can be used as photoaffinity ligands. It is well established that in membrane preparations [3H]flunitrazepam specifically photoaffinity labels polypeptides with Mr approx. 50000 (Mohler et al., 1980; Sieghart & Karobath, 1980) . Accordingly, in the purified receptor preparations, it is the a-subunit that is specifically photoaffinity-labelled with flunitrazepam and is thus considered to carry the benzodiazepine binding site (Stephenson et al., 1986a Kirkness & Turner, 1986a) .
The subunits of the purified GABAA receptors that are photoaffinity labelled with flunitrazepam are summarized in Table 2 .
More recently, it was demonstrated that in rat cerebellar membrane preparations [3H]muscimol photoaffinity-labelled a polypeptide apparently having the same molecular size as that photolabelled by flunitrazepam (Cavalla & Neff, 1985; Asano et al., 1983) . Photoaffinity labelling studies with [3Hlmuscimol on purified GABAA receptor preparations, however, have shown that it is the f-subunit that is specifically labelled with [3H]muscimol (Casalotti et al., 1986; Deng et al., 1986) . This apparent anomaly is explained by the fact that the a and ,f polypeptides, which differ in apparent size by only 4 kDa, are not well enough resolved in SDS/PAGE to permit unambiguous assignation of the radioactivity to a single band in the membrane studies (Casalotti et al., 1986) . Both the benzodiazepine and muscimol photoaffinity labelling reactions occur with low efficiency in the purified preparations. The maximum reported labelling of reversible sites in the purified receptor, where this has been studied quantitatively, was 25 % (Stephenson et al., 1986a) and 7.5 % (Casalotti et al., 1986) of the initial reversible binding sites for flunitrazepam and muscimol respectively (Casalotti et al., 1986) . The pharmacological specificity for the respective photoaffinity labelling reactions nevertheless suggests that these reactions are representative of the entire receptor population and accordingly that it is the a subunit that carries the benzodiazepine binding sites and the f-subunit the agonist or GABA binding sites.
Antibody studies. Monoclonal and polyclonal antibodies have been raised against the GABAA receptor Haring et al., 1985; Stephenson et al., 1986b; Mamalaki et al., 1987) . From these studies three important conclusions were drawn with regard to the structure of the receptor. Firstly, the group of Mohler in Switzerland has reported 22 monoclonal antibodies raised using as antigen a partially purified GABAA receptor from bovine cerebral cortex . The monoclonal antibodies were able to distinguish four epitopes of the receptor which were defined by a combination of immunoblotting, species specificity and competition in a solid-phase antibody binding assay . Of particular significance was that monoclonal antibody bd-17 was subunit-specific and monoclonal antibody bd-24 was a subunit-specific in Western blots .
Secondly, polyclonal antibodies raised against the GABAA receptor purified in the sodium deoxycholate/ Triton media with the expression of GABA and benzodiazepine binding sites only, specifically co-immunoprecipitated the GABA, benzodiazepine and TBPS binding sites from crude CHAPS extracts (Stephenson et al., 1986b) . This further supports the hypothesis formulated from the purification studies that all the binding sites are present in a single entity. This was later shown, also, for the above-described monoclonal antibodies .
Thirdly, Mamalaki et al. (1987) have described a monoclonal antibody, 1A6, which in Western blots recognizes both the a and the /8 subunits of the receptor purified from bovine cerebral cortex. It was demonstrated that the epitope was not the carbohydrate moiety common to the a and , subunits and it was concluded that the a and , polypeptides have a limited homology at the primary structural level (Mamalaki et al., 1987) . Furthermore, antigenic cross-reactivity between species was demonstrated in immunoblots and these findings supported the protein chemistry studies in that the GABAA receptor structure is conserved not only at the level of the subunit composition but also at the epitope level Mamalaki et al., 1987; Stephenson et al., 1986b) . Molecular cloning of the GABAA receptor cDNAs A major advance in the understanding of the GABAA receptor was achieved in a collaborative study between the groups of Eric Barnard in Cambridge and Peter Seeburg (then at Genentech Inc. in San Francisco). These groups reported the complete primary structure of the a subunit and of the subunit of the bovine GABAA receptor as deduced from the corresponding cDNAs (Schofield et al., 1987) . The approach that was taken was to obtain several non-contiguous partial amino acid sequences of the receptor (using CNBr or enzymic cleavages and h.p.l.c.). Three of the sequences derived were used for the construction of 'best guess' oligodeoxyribonucleic acid probes. These were employed to screen both a bovine and a calf cerebral cortex cDNA library to isolate GABAA receptor cDNAs which contained the entire protein-coding regions (Schofield et al., 1987) .
The deduced protein sequences of the a and , polypeptides showed several common features. Each has an N-terminal 25-30 residues which is characteristic of the cleavable signal peptide for integral membrane and secretory proteins. The respective hydropathy profiles of the mature polypeptides revealed that each subunit has four hydrophobic membrane-spanning domains (M1-M4) (Fig. 2) and further, each contained potential Nglycosylation sites, two for the a subunit and three for (a) Hydropathy profiles for the bovine GABAA receptor a subunit, the rat glycine receptor 48 kDa subunit and the bovine nicotinic acetylcholine receptor a subunit. The hydropathy profiles were computed according to Kyte & Doolittle (1982) with a window size of 17 residues plotted with a 1-residue interval as described in Schofield et al. (1987) . M1, M2, M3 and M4 are the putative membranespanning domains for each of the respective polypeptides. (b) Diagonal matrix (DIAGON) conservative homology comparison computed using the mutation data matrix MDM78 (Staden, 1982) of the bovine GABAA receptor , subunit versus the bovine GABAA receptor a subunit (left) and the rat glycine receptor 48 kDa subunit versus the bovine GABAA a subunit (right). The points correspond to mid-points of 21-residue spans giving a doublematching probability of < 0.0005. The sequence regions of strong similarity between each pair by this criterion, which includes both strictly conservative replacements and sequence identities, are revealed by the unbroken diagonal segments (Schofield et al., 1987) . the subunit in the predicted extracellular domains. In addition, the subunit was found to contain a potential intracellular site for phosphorylation by cyclic AMPdependent protein kinase. The lengths of the mature Vol. 249 I / / / polypeptides are 456 amino acids (Mr 44000) for the a subunit, and 474 amino acids (Mr 55000) for the f subunit (Schofield et al., 1987) . These values agree well with those predicted from the protein chemistry studies on the respective deglycosylated subunits (Mamalaki et al., 1987) . Again, as antibody evidence has indicated (Mamalaki et al., 1987) , the a and ft subunits were found to have definite sequence homology (Schofield et al., 1987) . The sequence identity between subunits was 35 %, while homology based on identities plus conservative substitutions was 57 % (Schofield et al., 1987) .
This strongly suggests that both subunits have evolved from a common ancestral gene. The predicted transmembrane topology of the GABAA receptor with the four membrane-spanning regions is with the N-terminus and the C-terminus both on the extracellular side of the membrane (Schofield et al., 1987) . With this model, the divergent region of the polypeptides is that which occurs between the M3 and the M4 membrane domains, where no sequence homology is found. This is the region which contains the phosphorylation site (residues 405-409, Arg-Arg-Arg-Ala-Ser, in the ft subunit) which would then be intracellular (Schofield et al., 1987) . The Nterminal region would be expected to contain the binding sites for agonists and the benzodiazepines, which have both been shown to be located extracellularly (Klotz et al., 1984; Czajkowski & Farb, 1986) . Further, it was noted (Schofield et al., 1987) that the general architecture of the GABAA receptor polypeptides was similar to that for another ligand-gated ion channel, the nicotinic acetylcholine receptor (for review see McCarthy et al., 1986) , i.e. a large N-terminal hydrophilic domain with four hydrophobic regions. Indeed, it was found that there was amino acid sequence identity between the GABAA receptor subunits and all known nicotinic acetylcholine receptor sequences in the specific regions of the chains. These are the M1 transmembrane region and parts of the N-terminal region where the sequence identity is 34 %, but the homology is 62 % based on the same conservative substitutions that are employed for the GABAA receptor subunit comparisons (Schofield et al., 1987) . A common structure of particular interest is an extracellular predicted ft-structural loop which can be formed by the disulphide bonding of two conserved cysteine residues (positions 139 and 153 in the GABAA receptor oc-subunit sequence). This loop has also been found in all nicotinic receptor subunits and in the receptor for the inhibitory neurotransmitter glycine: the sequence of one subunit (48 kDa) of that receptor was concurrently reported (Grenningloh et al., 1987) . The glycine receptor, like the GABAA receptor, is a ligandgated chloride ion channel and has been shown to have a heterologous oligomeric structure (Pfeiffer et al., 1982) . A similar predicted structural architecture was found for the 48 kDa glycine receptor polypeptide as that for the nicotinic acetylcholine receptor and the GABAA receptor subunits (Grenningloh et al., 1987; Schofield et al., 1987) . Further, the amino acid sequence identity and homology that is found between the 48 kDa glycine receptor subunit and the GABAA receptor a subunit i.e. of the order of 50 % homology (Stevens, 1987) , is correspondingly higher than was found between either of these and the nicotinic receptor subunits. These results indicate that there exists a superfamily of ligand-gated anion and cation channels (Schofield et al., 1987; Grenningloh et al., 1987) .
Functional expression of the GABAA receptor
The availability of the cDNAs encoding the GABAA receptor polypeptides permitted the evaluation of the hypothesis from the protein purification studies that the minimum requirement for functional GABAA receptor formation to include the GABA-gated chloride ion channel activity is the a and f subunits only. The elegant Xenopus oocyte translation system was used previously to show that following the microinjection of whole brain mRNA from chick (Smart et al., 1983) and rat (Houamed et al., 1984) sources, functional GABAA receptors were introduced into the oocyte surface membrane. The properties of these translated receptors were identical with those of the native GABAA receptor, in that the receptors were introduced into the oocyte membrane in the correct orientation with the drug binding sites being located extracellularly; the GABAA receptors had the correct pharmacological specificity and electrophysiological studies showed that the properties of the channel e.g. halide selectivity and desensitization phenomena, Van Renterghem et al., 1987) were as seen in vivo. Schofield et al. (1987) have now demonstrated clearly that following the microinjection of both the pure a subunit and the f subunit RNAs, GABA responsiveness is conferred on the Xenopus oocyte cell membrane. The microinjection of the a subunit RNA or the ,8 subunit RNA alone does not induce the response to GABA. The pharmacological specificity and the channel properties are those expected for the GABAA receptor and, importantly, it was shown that the allosteric sites for both the benzodiazepines and the barbiturates are present because the facilitation of the GABA responses by both these classes of compounds was observed in the oocytes microinjected with a and ft RNAs (Schofield et al., 1987) . These experiments confirm that the minimum requirement for GABAA receptor function which includes all the interacting drug binding sites is the presence of the a subunit and of the f8 subunit. Fig. 3 summarizes all the structural information that is now known about the GABAA receptor in the form of a hypothetical diagrammatical representation of the protein.
GABAA receptor heterogeneity
Earlier in this review the different classes of GABA receptor were discussed. There is also a substantial body of indirect evidence to support the existence of multiple 'central specificity' benzodiazepine binding proteins.
These are firstly, that the triazolopyridazines and the ft-carbolines displace benzodiazepine binding activity with a Hill coefficient < 1.0 (Squires et al., 1979; Nielsen & Braestrup, 1980) . This led to the proposal of the existence of Type I and Type II benzodiazepine receptors which have high affinity and low affinity respectively for the benzodiazepine binding site. This apparent heterogeneity of receptor sites has a brain-regional distribution as demonstrated in binding studies (Nielsen & Braestrup, 1980) and was further extrapolated to receptor autoradiographic studies (Young et al., 1981 The GABAA receptor are only those that are located adjacent to the ends of the membrane domains and that are assumed to be involved in the chloride ion binding. The inner core of the anion channel itself is postulated to be formed by the four copies of the M2 helix (contributed by each of the four subunits) and the presence of serine and threonine residues within this domain is thought to be essential for the flow of the chloride ions. Reprinted from Schofield et al. (1987) with the kind permission of Macmilllan Magazines Ltd.
terized in the rat, where it was shown that it had a brain regional distribution (Sieghart & Karobath, 1980; ; Table 3 ), as well as differences in post-natal development (Sieghart & Mayer, 1982) , in trypsin sensitivity (Sieghart et al., 1987) and in the pharmacological specificity of labelling which correlate with the known distribution and properties of the Type I and Type II benzodiazepine binding sites. The benzodiazepine binding polypeptides have so far always been shown to be associated with GABA receptors (Sieghart & Karobath, 1980) . Indeed, for the examples where there is only one benzodiazepine photoaffinity labelled subunit, such as in the rat and the porcine cerebellum, the coexistence of the unlabelled ,6 subunit was demonstrated by both purification studies (Kirkness & Turner, 1986a) and monoclonal antibody immunoblots . The function of the multiple benzodiazepine binding subunits is unknown. The possibility that they are proteolytic products derived from a single polypeptide has been excluded (Sieghart & Karobath, 1980) . However, Sweetnam & Tallman (1986) have reported brain-regional heterogeneity with respect to the carbohydrate moieties of the photolabelled subunits in the rat. It is possible that post-translation modification differences could thus account for the apparent heterogeneity in SDS/PAGE. All the above-documented evidence of GABAA receptor subtypes is indirect, and it must be stressed that so far no isoforms of the native GABAA receptor have been isolated although in some purified receptor preparations the presence ofmore than two subunits has been reported (Table 2) . Where the homogeneity of the pure GABAA receptor was assessed, a single homogeneous species was found (Stephenson et al., 1986b) . Thus, it is reasonable to conclude that if isoforms of the receptor do exist they must have remarkably similar properties. The idea of the receptor subtypes is an attractive hypothesis in terms of function, where it has been speculated that there should be a benzodiazepine receptor which mediates anxiolytic mechanisms and one which mediates the sedative properties of the benzodiazepines (Braestrup & Nielsen, 1982) . In support of this, Akaike et al. (1986) recently described an electrophysiological study which suggested the presence of at least two different GABA receptor- Vol. 249 chloride ionophore complexes. The availability of the cDNAs encoding the bovine a and , subunits will be a powerful tool with which to search for related expressed protein sequences to answer the question of GABAA receptor isoforms. It is also worth noting that, so far, I have considered the coexistence of the GABA, benzodiazepine and chloride channel sites within the same protein complex. There is evidence, again only indirect, that the GABAA sites and the channel sites can exist independently. For example, when the uptake of the soluble binding sites onto the benzodiazepine affinity column was studied quantitatively, it was found that the percentage of the benzodiazepine binding sites retained was higher than that for the GABAA sites Stephenson, 1987) . Furthermore quantitative immunoprecipitation experiments also revealed differences in the percentage of the GABA, benzodiazepine and TBPS sites that were coprecipitated . There are reported differences in the distribution of GABAA and benzodiazepine binding sites, particularly in the cerebellum (summarized in Richards et al., 1986 ) and indeed, GABAA responses have been found in astrocytes (Kettenman et al., 1987) whereas only the presence of the peripheral-type benzodiazepine binding protein has been described in these cells. The significance of these observations is not clear. A tentative explanation may be that perhaps homo-oligomeric complexes can exist but their function is as yet unknown.
Conclusions
It is just 10 years since the specific binding sites for the benzodiazepines in nervous tissue were first described. The discovery that these binding sites coexisted on the GABAA receptor facilitated greatly the purification of this important brain protein which culminated recently in the determination of the complete primary structure of the receptor. The isolation of the respective cDNAs encoding the receptor polypeptides represents an important advance in this field, and one can anticipate that, in the near future, site-directed mutagenesis studies in combination with the translation system of the Xenopus oocyte will yield more detailed information on the molecular architecture of the protein, in particular the location of the drug binding sites and the chloride ion channel. The possibility exists now of synthesizing chimeric receptor molecules; for example, will it be possible to induce glycine activation of a GABA receptor chloride ion channel?
The availability of the cDNAs should also permit approaches to answer the questions that conventional biochemical methodology has so far failed to answer. For example, large scale production of the GABAA receptor by coexpression of the respective cDNAs in cell lines or yeast should allow the determination of the respective drug binding site and the subunit stoichiometry, both of which are still unclear. Further, this may provide a convenient means to study the agonist affinity states of the receptor to rationalize the well-established conundrum that the concentrations of GABA required to elicit the physiological response are orders of magnitude higher than those required for receptor binding. There is also the question of the GABAA receptor isoforms: do they exist and, if so, do they each have a unique function? The field of GABAA receptor research enters a new era.
